CYRXCryoport, Inc.
Pharmaceutical Preparations
- Revenue
- $176M
- 12% YoY
- Operating margin
- -20.9%
- 73% YoY
- EBITDA
- −$9M
- 90% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$268M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashFired-11% of net incomeCash flow under 80% of net income
- Dilutive SBCClear6% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-117% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear3% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $223M | $237M | $169M | $157M | $176M | 12% |
| Operating income | −$18M | −$32M | −$101M | −$122M | −$37M | 70% |
| Net income | −$276M | −$37M | −$100M | −$115M | $78M | 168% |
| Operating cash flow | $8M | −$2M | −$757K | −$16M | −$9M | 47% |
| Capex | $24M | $22M | $39M | $17M | $16M | 4.7% |
| Stock-based comp | $15M | $20M | $20M | $17M | $10M | 39% |
| Buybacks | $0 | $38M | — | — | $10M |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $2M | $3M | 22 | 105 |
| FY2024 | $2M | $963K | 18 | 101 |
| FY2023 | $2M | $1M | 35 | 104 |
| FY2022 | $2M | −$7M | 40 | 107 |
| FY2021 | $5M | $10M | 135 | 140 |